Help
Subscribe


GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy

 24 February 2018

Advanced search
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy Profile of Roy Pounder

Home

News  
Journals
Review Articles
Slide Atlas
Video Clips
Online Books
Advanced Digestive Endoscopy
Classical Cases
Conference Diary
PubMed
International GH Links
USA GH Links
National GH Links
National GI Societies
Other Useful Links




Emails on Gastroenterology and Hepatology
the National AIDS Treatment Advocacy Project
Visit the gastroenterology section of the EUMS

News

Appendicectomy in ulcerative colitis patients with primary sclerosing cholangitis

The effects of appendicectomy in inflammatory bowel disease require further study in order to identify any influence on the extent of colitis, concludes an Australian study in the latest issue of Gut.

News image

fiogf49gjkf04

Appendicectomy, like smoking, is known to influence the clinical behavior of ulcerative colitis. However, in patients with coexistent primary sclerosing cholangitis (PSC), the phenotype of their disease already differs from those patients with ulcerative colitis (UC) alone.

Researchers have therefore examined the interaction of appendicectomy and PSC on the epidemiology and clinical course of ulcerative colitis, to see what further differences may be observed.

Patients from the Brisbane IBS Research Group database were used to carry out the study, with controls taken from the Australian twin registry.

A total of 78 PSC-inflammatory bowel disease (PSC-IBD) patients, 12 pure PSC patients, and 294 UC patients were matched with 1466 controls by sex and birth cohort that comprised randomly selected twins from each twin pair.

Investigations were then carried out into the effects of appendicectomy, smoking, or PSC on various clinical factors.

These were onset of disease, disease extent, disease severity (as identified by immunosuppression-colectomy or liver transplant) and disease related complications. Disease related complications were classed as high grade dysplasia, colorectal cancer, or cholangiocarcinoma.

All investigations were analyzed using univariate and multiple logistic regression analyses.

The researchers found that PSC-IBD patients suffered from more extensive colitis that did UC patients, but required less immunosuppression, a finding which was independent of disease extent.

Furthermore, such patients had an increased likelihood of having high grade dysplasia or colorectal cancer than did UC patients.

Appendicectomy can influence ulcerative colitis
Gut

In the PSC groups there was no difference in appendicectomy rates when compared with the control group.

This contrasted dramatically with the UC patients, who were four times less likely to have undergone appendicectomy than were subjects from the control group.

When examining the affect of appendicectomy, there appeared to be an approximate five year delay in the onset of intestinal (PSC-IBD or UC) or hepatic (PSC) disease in those patients who had undergone prior appendicectomy. This finding was independent of smoking.

However, appendicectomy did not independently alter the extent or severity of disease in PSC.

This was not the case in UC, where prior appendicectomy was associated with more extensive disease but with a lesser requirement for immunosuppression or colectomy for the treatment of colitis.

Non-statistically significant trends for high grade dysplasia or colorectal cancer were identified with appendicectomy in both PSC-IBD and UC. Despite the lack of statistical significance, colorectal cancer appeared more frequent with appendicectomy in a meta-analysis of the available UC data from this and another Australian study.

The researchers conclude that unlike UC, appendicectomy did not significantly influence the prevalence of the PSC groups, or the extent of colitis in PSC-IBD. However, as with UC, appendicectomy did appear to delay their onset.

They add that extensive milder colitis, which is characteristic of PSC-IBD, relates to other poorly understood factors.

Further prospective studies, they say, are required to determine any influence of appendicectomy on the extent of colitis in IBD and an associated dysplasia or colorectal cancer.

Gut 2004; 53(7): 973
30 June 2004

Go to top of page Email this page Email this page to a colleague

 23 February 2018 
Patients on antithrombotic agents undergoing emergency and elective endoscopy
 23 February 2018 
Heavy metals on a gluten-free diet
 23 February 2018 
MRI and NAFLD
 22 February 2018 
Outcomes with Crohn’s after infliximab withdrawal
 22 February 2018 
Elderly onset of IBD

 22 February 2018 
Autophagy enhancers
 21 February 2018 
Management of hemorrhoids in the USA
 21 February 2018 
Adalimumab and infliximab in biologic-naïve Crohn's
 21 February 2018 
Cystic fibrosis and colorectal cancer
 20 February 2018 
Complications and surveillance colonoscopies
 20 February 2018 
Treatment algorithm for polyp cancers
 20 February 2018 
Predictors of postoperative infection in Crohn's
 19 February 2018 
Screening colonoscopy in the right and left colon
 19 February 2018 
NAFLD prevalence in the USA
 19 February 2018 
Fructans in children with IBS

 16 February 2018 
Inflammatory bowel diseases are global diseases
 16 February 2018 
Undetected celiac in the elderly
 16 February 2018 
Fructans induce non-celiac gluten sensitivity
 15 February 2018 
NSAIDS and GI damage
 15 February 2018 
Oral direct-acting antiviral treatment for Hep C virus genotype 1
 15 February 2018 
Primary vs secondary surgery for the presence of lymph node metastasis
 14 February 2018 
Predicting adenoma detection rate
 14 February 2018 
Normal bowel frequency characterization in the USA 
 13 February 2018 
Personalising treatment options for IBS
 13 February 2018 
Prebiotics improve endothelial dysfunction
 13 February 2018 
Diagnostic criteria for a Rome IV functional gastrointestinal disorders
 12 February 2018 
Visceral hypersensitivity and functional GI disorders
 12 February 2018 
Depression and aggressive IBD
 12 February 2018 
Variability in interpretation of endoscopic findings impacts patient management
 09 February 2018 
Treatment of choice for anastomotic stricture in IBD
 09 February 2018 
PRO measurement information system 
 09 February 2018 
Overall disease severity indices for IBD
 08 February 2018 
Prediction of endoscopically active disease

 08 February 2018 
Steroid-refractory acute severe ulcerative colitis
 08 February 2018 
Decision aid used by IBD patients
 07 February 2018 
Ursodeoxycholic acid combined with bezafibrate for itching
 07 February 2018 
Change in microbiome in gastritis vs gastric carcinoma
 07 February 2018 
Colorectal cancer and primary sclerosing cholangitis-IBD
 06 February 2018 
Risk of death after liver transplantation
 06 February 2018 
Crohn’s disease vs refractory pouchitis
 06 February 2018 
Support for functional dyspepsia symptom diary
 05 February 2018 
Helicobacter spp influence on GI tract 
 05 February 2018 
No link found between severe reflux and all-cause mortality 
 05 February 2018 
Psychological distress in PPI non-responders
 02 February 2018 
Assessing psychosexual impact of IBD
 02 February 2018 
Decrease in overall mortality with cholera vaccination
 02 February 2018 
Diagnostic performance of fecal immunochemical tests
 01 February 2018 
Screening frequency with family histories of colorectal cancer
 01 February 2018 
IBD and sport participation
 01 February 2018 
Life with a stoma 
 31 January 2018 
Aprepitant and gastroparesis 
 31 January 2018 
Anesthesia risk in colonoscopy
 31 January 2018 
GED-0301 for Crohn's Disease
 30 January 2018 
Intestinal dysbiosis and allergic diseases in infants
 30 January 2018 
Fructans and IBS symptoms in children
 29 January 2018 
Dosing calculator for therapy optimization in IBD
 29 January 2018 
Glecaprevir–pibrentasvir for in HCV
 29 January 2018 
Food allergen injections in eosinophilic esophagitis
 29 January 2018 
Reliability of the IBD index
 26 January 2018 
Tofacitinib vs biological therapies for ulcerative colitis

Blackwell Publishing


GastroHep.com is a Blackwell Publishing registered trademark
© 2018 Wiley-Blackwell and GastroHep.com and contributors
Privacy Statement
Disclaimer
About Us